Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repeated-dose RO5459072 in healthy volunteers
NL-OMON42481Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in lupus nephritis (LN) and Sjögren's syndrome comparing RO5459072 ascending-dose cohorts with Placebo control (2 arms). Primary endpoint: Pharmacodynamic effects on cathepsin S activity and immune function. Started Aug 2015; status: active, not recruiting.
02
Drugs
petesicatib
03
Conditions
lupus nephritis (LN)Sjögren's syndrome
Beyond the preview
Go deeper on NL-OMON42481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42481.